When was Volastra founded?

Volastra was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Volastra located?

Volastra is headquartered in New York City, United States. It is registered at New York City (United States).

Is Volastra a funded company?

Volastra is a funded company, having raised a total of $117M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 11, 2020.

When was the latest funding round of Volastra?

Volastra's latest funding was a $***** Series B round on Sep 08, 2025, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.33B in funding in 2026 to date.

Where does Volastra rank among its competitors?

Volastra ranks 102nd amongst 849 active competitors, of which 306 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Volastra, which secured $30.1M in Sep, 2025.

Who are the top competitors of Volastra?

Volastra's top competitors include Alnylam, Spark Therapeutics and Abcellera Biologics. Among them, Volastra secured the most recent funding round in September, 2025.

Volastra - 2026 Company Profile, Team, Funding & Competitors

Volastra is a series B company based in New York City (United States), founded in 2019 by Samuel Bakhoum, Lewis Cantley and Olivier Elemento. It operates as a Developer of therapeutics for cancer treatment. Volastra has raised $117M in funding from investors like Polaris Partners, Arch Venture Partners and Vida Ventures. The company has 849 active competitors, including 306 funded and 187 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Abcellera Biologics.

Company Details

Developer of therapeutics for cancer treatment. The company is developing compounds to target chromosomal instability and related pathways to inhibit genomic instability and disease progression. It also developing proprietary imaging technologies to identify chromosomal instability cancers.

Website: volastratx.com
Email ID: *****@volastratx.com
Registered Address: New York City (United States)

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Series B

Total Funding

$117M in 5 rounds

Latest Funding Round

Series B, Sep 08, 2025, $*****

Investors

Polaris Partners & 10 more

Ranked

102^nd among 849 active competitors

Similar Companies

Alnylam & 1071 more

View Volastra's full profile

Volastra is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Volastra Therapeutics, Inc. CIN: 84-1816753 , Belgium, Active	Dec 31, 2018	-	21 (As on Dec 31, 2021)	-

Volastra has raised a total funding of $117M over 5 rounds. Its first funding round was on Feb 11, 2020. Volastra has 11 institutional investors.

Here is the list of recent funding rounds of Volastra:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 08, 2025	9324228	Series B	8523006	5695523	6657738	4576508
May 17, 2024	6066926	Series A	9754818	1495401	7197241	1654959
Mar 07, 2023	3336982	Series A	2413674	5231191	Polaris Partners & 1 more	Lilly & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Volastra's funding rounds and investors

The founders of Volastra are Samuel Bakhoum, Lewis Cantley and Olivier Elemento.

Here are the details of Volastra's key team members:

Samuel Bakhoum: Co-Founder of Volastra.
Lewis Cantley: Co-Founder of Volastra.
Olivier Elemento: Co-Founder of Volastra.

View details of Volastra's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Volastra include Alnylam, Spark Therapeutics and Abcellera Biologics. Here is the list of Top 10 competitors of Volastra, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
5th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
8th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
102nd	Volastra 2019, New York City (United States), Series B	Developer of therapeutics for cancer treatment	$117M	Lilly, B Capital & 9 others	55/100